Alliance Global Partners lowered the firm’s price target on Tenon Medical (TNON) to $2.50 from $3 and keeps a Buy rating on the shares, citing lower forecasts after Tenon reported Q1 results that were within the firm’s expectations, including a revenue shortfall offset by lower expenses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNON: